Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000667597 | SCV000792075 | likely pathogenic | Bardet-Biedl syndrome 1 | 2017-06-08 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000667597 | SCV000893908 | pathogenic | Bardet-Biedl syndrome 1 | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001377611 | SCV001574991 | pathogenic | Bardet-Biedl syndrome | 2022-01-07 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 552356). Disruption of this splice site has been observed in individual(s) with retinitis pigmentosa (Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is present in population databases (rs748523268, gnomAD 0.07%). This sequence change affects an acceptor splice site in intron 8 of the BBS1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in BBS1 are known to be pathogenic (PMID: 12118255). |